NEW YORK (GenomeWeb News) – Les Laboratoires Servier and Prognomix today announced a deal to identify novel targets for the development of type 2 diabetes and metabolic disease treatments.
The research and development deal will use Prognomix's platform that is based on genomics and bioinformatics technologies, a database of phenotypic and genotypic data, and results from the analysis of the data. The data analysis serves as the foundation of a knowledgebase that will be used by Servier and Prognomix.
The knowledgebase results from what the partners said is the largest clinical study ever conducted on type 2 diabetes called Advance, for which Servier was the main sponsor.
As part of the deal, Servier will make a "contract signature fee payment" of an undisclosed amount. In return, the French pharma can obtain the rights to use targets resulting from the partnership.
Prognomix is a privately held personalized medicine firm based in Montreal, focused on discovering genetic signatures that may be predictive of disease and developing them for clinical use.